BioSpace News Archive

Aspen Surgical Products, Inc., a leader in surgical disposable products, has appointed Jason Krieser as their new Chief Executive Officer.

Nominees bring extensive expertise in the fields of oncology drug development and commercialization, biopharmaceutical company financing and strategic operations

Eleusis, a clinical stage life science company established to develop the therapeutic potential of psychedelics, today announced the publication of its sponsored preclinical research in the American Chemical Society’s journal Chemical Neuroscience, which suggests that psychedelics may have more persistent antidepressant therapeutic efficacy than ketamine

West Virginia Leads State List for First Time this Season and Mid-Atlantic Cities Comprise Top Three Markets

Aerin Medical Inc., a company focused on minimally invasive solutions for chronic nasal conditions, today announced U.S. Food and Drug Administration (FDA) clearance and U.S. launch of the company’s second product, the RhinAer™ Stylus, an innovative device for nonsurgical treatment of chronic rhinitis.

Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated diseases, today announced that the company will host a conference call on Thursday, March 12, 2020, at 8:00 a.m. ET to discuss financial results for the quarter and year ended December 31, 2019 and provide a corporate update

ALR Technologies Inc. (“ALRT” or the “Company”)(OTCPINK: ALRT), the diabetes management company, has been approved for its common stock to be DWAC FAST and has submitted an application to upgrade the trading of its common stock to the OTCQB ® Venture Market. OTCQB Trading Application The Company is pleased to announce that it has applied to the OTC Markets Group Inc. to upgrade trading from the Pink Market to the OTCQB Venture Market.

Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) (“Galmed” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of Aramchol, a liver targeted, oral, SCD1 modulator, currently in Phase 3 clinical trial for the treatment of nonalcoholic steatohepatitis (NASH) and fibrosis announced today that it will host a conference call.

LabVantage Solutions, Inc., the leading provider of laboratory informatics solutions and services including purpose-built LIMS solutions that allow labs to go live faster and at a lower total cost, today announced the North American introduction of its Medical Suite Laboratory Information System (LIS) specially designed for use in medical and healthcare settings.

AVROBIO, Inc. announced that the company has granted non-statutory stock options for the purchase of up to an aggregate of 259,750 shares of the company’s common stock to nine new employees as inducement awards under the company’s 2019 Inducement Plan, in accordance with Nasdaq Listing Rule 5635.